Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Premarket analyst action - healthcare

Published 11/09/2017, 08:35 AM
Updated 11/09/2017, 08:35 AM
© Reuters.  Premarket analyst action - healthcare
  • Nektar Therapeutics (NASDAQ:NKTR) initiated with Buy rating and $35 (16% upside) price target by Canaccord Genuity.
  • AnaptysBio (NASDAQ:ANAB) initiated with Buy rating and $101 (54% upside) price target by Jefferies.
  • Acorda Therapeutics (NASDAQ:ACOR) initiated with Neutral rating and $27 (6% downside risk) by Oppenheimer.
  • GTx (NASDAQ:GTXI) initiated with Buy rating and $16 (113% upside) price target by Stifel.
  • Idera Pharmaceuticals (NASDAQ:IDRA) initiated with Buy rating and $4 (126% upside) price target by H.C. Wainwright.
  • Biogen (NASDAQ:BIIB) initiated with Outperform rating and $350 (12% upside) price target by Oppenheimer.
  • Alnylam Pharmaceuticals (NASDAQ:ALNY) upgraded to Overweight by JPMorgan (NYSE:JPM).
  • Amphastar Pharmaceuticals (NASDAQ:AMPH) downgraded to Market Perform by Raymond James.
  • Amedisys (NASDAQ:AMED) downgraded to Hold by Benchmark.
  • Egalet (NASDAQ:EGLT) downgraded to Hold by Gabelli.
  • QuintilesIMS (NYSE:Q) downgraded to Neutral by MIzuho.
  • Selecta Biosciences (NASDAQ:SELB) downgraded to Neutral by UBS.
  • Source: Bloomberg
  • Now read: Acorda Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.